Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 12 [hp_C]/1 | PELLET | ORAL | 37662-2044 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-2046 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-2049 |
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Ruthenium, you must consult a qualified healthcare professional.
| 30 [hp_C]/1 | PELLET | ORAL | 37662-2045 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-2047 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-2043 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-2048 |
Detailed information about Ruthenium
Ruthenium, primarily utilized as the radioisotope Ruthenium-106, is a transition metal used in plaque brachytherapy for ocular tumors. It belongs to the class of therapeutic radiopharmaceuticals and specialized medical allergens.
The 'dosage' of Ruthenium-106 is not measured in milligrams but in Gray (Gy), which is a unit of absorbed radiation dose. The standard prescription typically aims to deliver 70 to 100 Gy to the apex (top) of the tumor and significantly higher doses (up to 400-600 Gy) to the base of the tumor.
Healthcare providers calculate the dosage based on:
Ruthenium-106 is used in pediatric patients primarily for retinoblastoma. The dosing principles are similar to adult dosing, focusing on delivering a tumoricidal (cancer-killing) dose while sparing the developing eye tissues. Because children’s eyes are smaller, specialized smaller plaques are often utilized. Pediatric treatment requires a multidisciplinary team including a pediatric oncologist and an ocular oncologist.
Because Ruthenium plaques are sealed sources and do not enter systemic circulation, no dosage adjustments are required for patients with kidney disease. However, the surgical anesthesia required for plaque placement must be managed carefully in these patients.
There are no specific dosage adjustments for liver impairment, as the drug is not metabolized by the liver.
Elderly patients may have thinner sclera (the white of the eye), which requires the surgeon to use caution when suturing the Ruthenium plaque. The radiation dose remains focused on the tumor characteristics rather than the patient's age.
Ruthenium is administered through a two-stage surgical process:
Storage and Handling: Ruthenium plaques are high-level radioactive materials. They are stored in lead-lined containers in specialized nuclear medicine departments. Patients do not handle the medication themselves.
In the context of brachytherapy, a 'missed dose' is not possible in the traditional sense. However, if the plaque were to shift or become displaced (an extremely rare surgical complication), the radiation would not be delivered to the correct area. This is why follow-up imaging and secure suturing are critical.
An 'overdose' in Ruthenium therapy would involve leaving the plaque on the eye for longer than the calculated time. This could lead to excessive radiation damage to healthy eye structures, resulting in severe vision loss or radiation necrosis (tissue death). Medical physicists double-check all calculations to prevent this occurrence. If an over-exposure is suspected, the plaque is removed immediately, and anti-inflammatory treatments (like steroids) may be initiated to manage the radiation effect.
> Important: Follow all post-operative instructions provided by your surgical team. Do not rub the eye or engage in strenuous activity while the plaque is in place.
Because Ruthenium-106 delivers targeted radiation, side effects are primarily localized to the eye and the surrounding orbital tissue.
Ruthenium-106 is a radioactive material. While the plaque is designed to focus radiation inward toward the tumor, a small amount of radiation may escape outward. Patients undergoing treatment must follow 'Radiation Safety Precautions' as directed by the hospital's radiation safety officer. This may include maintaining a certain distance from pregnant women and small children during the few days the plaque is active on the eye.
No FDA black box warnings for Ruthenium. However, clinical guidelines emphasize that Ruthenium-106 should only be administered by physicians who are specifically trained in ocular oncology and radiation physics.
There are no absolute drug-drug contraindications that would prevent the use of a Ruthenium plaque, as it is a localized physical treatment. However, Live Vaccines should generally be avoided if the patient is also receiving systemic chemotherapy or is in a highly stressed physiological state following ocular surgery, though the Ruthenium itself does not cause immunosuppression.
FDA Pregnancy Category: Not Formally Assigned (Radioactive Source).
Ruthenium-106 is generally avoided during pregnancy. Ionizing radiation is a known teratogen (can cause birth defects). While the radiation from a Ruthenium plaque is highly localized to the eye, there is a small amount of 'scatter' radiation. If a pregnant woman requires treatment for a life-threatening ocular melanoma, a lead shield must be placed over the abdomen during the dwell period, and the risks must be discussed extensively with an obstetrician and an oncologist.
There is no evidence that Ruthenium-106 from a sealed ocular plaque enters the breast milk. However, due to the close physical proximity required for breastfeeding, a nursing mother with an active Ruthenium plaque on her eye could potentially expose the infant to small amounts of external radiation. It is generally recommended to use pumped milk or formula during the 2-7 days the plaque is attached to the eye.
Ruthenium-106 is an established treatment for pediatric retinoblastoma when the goal is to save the eye and avoid the side effects of external beam radiation (which can cause bone growth issues in the skull). Long-term monitoring is crucial in children to manage potential cataracts and retinal damage as the child grows.
Ruthenium-106 acts as a source for high-energy beta particles. The primary mechanism is the destruction of cellular DNA within the target tumor. Ruthenium-106 decays via beta-minus emission to Rhodium-106. Rhodium-106 then decays (with a very short half-life of 30 seconds) and emits the therapeutic beta particles with a maximum energy of 3.54 MeV. These particles penetrate approximately 5-8mm into the tissue, causing localized ionization that breaks DNA strands and generates free radicals, leading to cell death.
The pharmacodynamic effect is the reduction in tumor volume and the cessation of tumor growth. The 'onset' of action is immediate upon surgical application, but the 'effect' (tumor shrinkage) is slow, often taking months or even years to fully manifest on an ultrasound scan. Tolerance does not develop, as the mechanism is physical rather than biochemical.
| Parameter | Value |
|---|---|
| Bioavailability | 0% (Sealed source) |
Common questions about Ruthenium
In medicine, Ruthenium (specifically the isotope Ruthenium-106) is used as a localized radiation treatment for eye cancers like uveal melanoma and retinoblastoma. It is applied via a small, radioactive plaque that is surgically attached to the outside of the eye directly over the tumor site. This allows for a high dose of radiation to be delivered to the cancer while sparing much of the rest of the body from exposure. It is typically reserved for tumors that are relatively small to medium in height. Your ocular oncologist will determine if this form of brachytherapy is the best option for your specific tumor type.
The most common side effects of Ruthenium treatment are localized to the treated eye and include radiation retinopathy, cataracts, and dry eye. Radiation retinopathy involves damage to the retinal blood vessels and can lead to a gradual decrease in vision over several years. Cataracts, or clouding of the lens, are also very common but can usually be corrected with surgery later on. Some patients may also experience temporary redness or irritation from the surgical procedure itself. Because the radiation is localized, systemic side effects like hair loss or nausea are not expected.
There is no direct chemical interaction between the Ruthenium plaque and alcohol. However, patients are generally advised to avoid alcohol in the days surrounding their two surgical procedures (implantation and removal) to ensure the safest possible experience with anesthesia. Alcohol can also contribute to dehydration and may interfere with the healing process after surgery. Once the plaque has been removed and you have recovered from surgery, moderate alcohol consumption typically does not affect the outcome of the radiation treatment. Always consult your surgeon for specific post-operative dietary restrictions.
Ruthenium-106 is generally not recommended during pregnancy because ionizing radiation can be harmful to a developing fetus. While the radiation from an eye plaque is highly focused, there is always a small amount of 'scatter' radiation that could potentially reach the abdomen. If treatment is absolutely necessary to save the mother's life or sight, extreme precautions, such as lead shielding over the womb, must be used. Most doctors will explore alternative treatments or delay treatment if possible until after delivery. Pregnant women should discuss the risks and benefits in great detail with their oncology team.
While the Ruthenium plaque begins emitting radiation the moment it is placed on the eye, the visible effects on the tumor take time to appear. Unlike a surgical excision where the tumor is gone immediately, radiation causes the tumor to shrink slowly over months or years. Your doctor will monitor the progress using ultrasound and other imaging techniques during follow-up visits. In many cases, the goal of treatment is not just to make the tumor disappear but to 'kill' it so that it no longer grows or poses a risk of spreading to other parts of the body. Success is often defined as the stabilization or regression of the tumor size.
Ruthenium treatment cannot be 'stopped' by the patient because it is a surgically implanted device. The treatment is 'stopped' when your surgeon removes the plaque after the prescribed radiation dose has been delivered, which usually takes between 2 and 7 days. You cannot simply decide to end the treatment early without a second surgery. If the plaque were removed too soon, the tumor would not receive enough radiation to be destroyed, increasing the risk of cancer recurrence. If you have concerns about the treatment while the plaque is in place, you must contact your surgical team immediately.
In the context of Ruthenium brachytherapy, it is impossible to 'miss a dose' in the way you might miss a pill, because the radiation is delivered continuously while the plaque is attached to your eye. The only way the 'dose' could be interrupted is if the plaque were to become surgically displaced, which is extremely rare. If you notice any sudden change in the position of your eye patch or experience severe pain, you should contact your doctor immediately. The medical team ensures the correct dose is delivered by carefully calculating the 'dwell time' and performing the removal surgery at the exact scheduled time.
No, Ruthenium-106 treatment does not cause weight gain. Because the radiation is localized entirely to the eye and does not enter the bloodstream, it does not affect your metabolism, appetite, or hormones in a way that would lead to weight changes. Any weight changes experienced during treatment are likely due to other factors, such as stress, changes in physical activity due to surgery, or other medications you may be taking, such as systemic steroids. If you experience significant or unexplained weight changes, you should discuss them with your primary care physician.
Ruthenium plaques can generally be used alongside most other medications, but some precautions are necessary. Blood thinners (anticoagulants) are often paused before the surgical procedures to prevent bleeding complications. Additionally, some doctors may use 'radiosensitizing' drugs or anti-VEGF injections to enhance the effect of the radiation or treat its side effects. It is vital to provide your ocular oncologist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. This allows the team to manage any potential risks related to the surgery or the healing process.
Ruthenium-106 is not a 'brand name' drug but a radioactive isotope, so the concept of 'generic' vs. 'brand' does not apply in the traditional sense. However, the plaques themselves are manufactured by specific companies (such as BEBIG in Europe). Different centers may use plaques from different manufacturers, but they all contain the same active Ruthenium-106 isotope. Because this is a highly specialized, low-volume medical device, it is not found in standard pharmacies and is only available through specialized hospitals and cancer centers that are licensed to handle radioactive materials.
> Warning: Stop taking Ruthenium (contact your ocular oncologist) and seek immediate medical attention if you experience any of the following after your procedure:
Long-term monitoring is essential because radiation effects can manifest years after the Ruthenium plaque is removed. Chronic radiation retinopathy can lead to permanent scarring of the retina. Additionally, there is a theoretical, albeit very low, risk of secondary malignancies (new cancers) in the orbital area due to radiation exposure, though this is significantly lower with Ruthenium than with external beam radiation.
There are currently no standard FDA 'Black Box' warnings for Ruthenium-106 plaques, as they are regulated as medical devices/radioactive sources rather than systemic drugs. However, they are subject to strict Nuclear Regulatory Commission (NRC) or equivalent international regulations regarding the handling of radioactive materials. The primary 'warning' is the risk of permanent vision loss in the treated eye, which is a known and often unavoidable consequence of destroying a tumor located within the ocular structures.
Report any unusual symptoms or changes in your vision to your healthcare provider immediately. Regular follow-up appointments (typically every 3-6 months) are mandatory to monitor for these side effects.
Patients treated with Ruthenium require lifelong ophthalmic monitoring:
During the days the plaque is on the eye, the eye will be patched, and depth perception will be significantly impaired. Do not drive or operate heavy machinery while the eye is patched. After the plaque is removed, your doctor will advise when it is safe to drive, depending on the vision in your remaining eye.
There is no direct interaction between Ruthenium and alcohol. However, alcohol should be avoided immediately before and after the surgical procedures to minimize risks associated with anesthesia and to promote healing.
'Discontinuation' of Ruthenium therapy occurs when the surgeon removes the plaque. There is no 'withdrawal syndrome.' However, the biological effects of the radiation continue for months and years. Patients must not miss their follow-up appointments even if the 'drug' (the plaque) has been removed.
> Important: Discuss all your medical conditions, especially any history of eye surgery or autoimmune diseases, with your healthcare provider before starting Ruthenium brachytherapy.
There are no known food interactions with Ruthenium-106. Because it is not absorbed through the digestive tract, grapefruit juice, dairy, and high-fat meals do not affect its efficacy or safety.
Ruthenium-106 does not interfere with standard blood chemistry or hematology tests. However, the presence of the metal plaque will cause significant 'artifact' (interference) on MRI scans of the head. If an MRI is needed while the plaque is in place, the radiologist must be informed, though usually, MRIs are performed before or after the plaque duration.
Most interactions involving Ruthenium are pharmacodynamic (how the body reacts to the radiation) rather than pharmacokinetic (how the body processes a drug). For example, a drug that makes the retina more sensitive to light or radiation would have a pharmacodynamic interaction with Ruthenium.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect blood clotting or immune function.
There is no known cross-sensitivity between Ruthenium and other common medications. However, patients who have had previous adverse reactions to other forms of radiation therapy (like external beam radiation) may be at higher risk for severe tissue reactions to Ruthenium.
> Important: Your healthcare provider will evaluate your complete medical history and the specific dimensions of your tumor before prescribing Ruthenium.
Elderly patients are the most common recipients of Ruthenium for uveal melanoma. There are no specific age-related changes in how Ruthenium works, but elderly patients may have co-existing conditions like macular degeneration or diabetic retinopathy that make the eye more vulnerable to radiation damage. The surgical risks of anesthesia are also higher in this population.
No dosage adjustment is needed for patients with renal impairment. The physical decay of the isotope is independent of kidney function.
No dosage adjustment is needed for patients with hepatic impairment. The treatment is localized and does not involve liver enzymes.
> Important: Special populations require individualized medical assessment and a coordinated care plan between multiple specialists.
| Protein Binding | N/A |
| Physical Half-life | 373.59 Days |
| Effective Half-life | N/A (Not systemic) |
| Tmax | Immediate upon application |
| Metabolism | Physical decay to Rhodium-106 |
| Excretion | Surgical removal of the device |
Ruthenium belongs to the class of Therapeutic Radiopharmaceuticals and is categorized under the EPC (Established Pharmacologic Class) of Radioactive Isotope [EPC]. It is distinct from gamma-emitting sources like Iodine-125 due to its primary beta-emission profile.